Marizyme, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
May 16, 2022 at 11:30 am EDT
Share
Marizyme, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 6.12 million compared to USD 2.81 million a year ago. Basic loss per share from continuing operations was USD 0.15 compared to USD 0.08 a year ago.
Marizyme, Inc. is a multi-technology life science company. The Company is engaged in the development and commercialization of medical technologies that improves patient health outcomes. Its products include DuraGraft, MATLOC 1 and Krillase. DuraGraft is a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, thereby reducing the incidence and complications of graft failure and improving clinical outcomes post bypass surgery. MATLOC is a lab-on-chip digital screening and diagnostic device platform, which is being developed for quantitative chronic kidney disease (CKD) assessment. Krillase can be used in the treatment of chronic wounds and burns, and other clinical applications. Its DuraGraft is an endothelial damage inhibitor (EDI), indicated for cardiac bypass, peripheral bypass, and other vascular surgeries.
MARIZYME, INC. 
